Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 65, Issue 7, Pages 787-796Publisher
SPRINGER
DOI: 10.1007/s00262-015-1776-3
Keywords
CITIM 2015; Epigenetic modifier; DNA methyltransferase inhibitor; Decitabine; Immunotherapy; Ovarian cancer
Categories
Funding
- Ovarian Cancer Research Fund (Liz Tilberis Scholar award)
- Susan F. Smith Center for Women's Cancer
Ask authors/readers for more resources
Immunotherapy confers durable clinical benefit to melanoma, lung, and kidney cancer patients. Challengingly, most other solid tumors, including ovarian carcinoma, are not particularly responsive to immunotherapy, so combination with a complementary therapy may be beneficial. Recent findings suggest that epigenetic modifying drugs can prime antitumor immunity by increasing expression of tumor-associated antigens, chemokines, and activating ligands by cancer cells as well as cytokines by immune cells. This review, drawing from both preclinical and clinical data, describes some of the mechanisms of action that enable DNA methyltransferase inhibitors to facilitate the establishment of antitumor immunity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available